

BioXyTran Inc.

A Complex Carbohydrate Chemistry Drug Company

Forward Looking Statement

This Descriptive Presentation (the "Presentation") has been prepared by Bioxytran, Inc (the "Company") and recipients are not entitled to rely on the accuracy or completeness of the Presentation. Statistical information contained in this Presentation is based on information available to the Company that the Company believes is accurate. It is generally based on publications that are not produced for the purposes of securities offerings or economic analysis. The Company has not reviewed or included data from all sources and cannot assure prospective parties of the accuracy or completeness of the data included in this Presentation. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. The Company undertakes no obligation to update forward looking information to reflect actual results or changes in assumptions or other factors that could affect those statements.

This Presentation has not been filed or reviewed by the Securities and Exchange Commission ("SEC") or any securities regulatory authority of any state, nor has the SEC or any such authority passed upon the accuracy or adequacy of this Presentation. This Presentation does not constitute an offer to sell or solicitation of an offer to buy any securities. This Presentation does not purport to contain all information which may be material to a prospective party, and recipients of this Presentation should conduct their own independent evaluation and due diligence of the Company. Each recipient agrees, and the receipt of this Presentation serves as an acknowledgment thereof, that if such recipient determines to engage in a transaction with the Company, its determination will be based solely on the terms of the definitive agreement relating to such transaction and on the recipient's own investigation, analysis and assessment of the Company and the transaction. The Company does not intend to update or otherwise revise this Presentation following its distribution.

Platform Technologies Addressing 3 Major Problems

GLYCOVIROLOGY



PROBLEM ONE

STROKE

PROBLEM TWO

CANCER METASTASIS



PROBLEM THREE

The Problems

No Effective Treatment for Viral Infections



No Treatment for Early-Stage Stroke

No Effective Treatments for Cancer Metastasis

BioXyTran®

PROBLEM NUMBER #1

No Effective Treatment for Viral Infections

Problem #1: No Effective Treatment for Viral Infections

United States Virology Data



2600+ RNA Viruses Identified

No Broad-Spectrum solution for Viruses unlike Penicillin For Bacterial Infection

Vaccines are unable to keep pace with Mutations

In 1992 David Platt for the first time identified and named the Galectin

01

Bioxytran develops IP protected Galectin Antagonists

02

Most viruses need Galectin receptors to bind to cells

03

Galectin Antagonists block the binding and neutralize the virus

Key Leadership in Galectin Science

David Platt PhD, CEO, CSO, Chairman

40+ years of research in Galectins (carbohydrate-binding proteins)

Co-author of 2 Textbooks

Founder of 5 Public Companies

Publication of numerous Journal Articles and Patents

Developer of numerous drugs FDA regulatory clinical trials

Galectin Science Leader Resulted in

4,000+

Journal Articles on Target Receptors

First Expression of the "Galectin" Protein - 1993

Biochemistry **1993,** *32,* 4455–4460 4455

Structure–Function Relationship of a Recombinant Human Galactoside-Binding Protein†

Josiah Ochieng,‡ David Platt,‡§ Larry Tait,‡ Victor Hogan,‡ Tirza Raz,‡ Pnina Carmi,‡⊥ and Avraham Raz*,‡

Metastasis Research Program, Michigan Cancer Foundation, 110 East Warren Avenue, Detroit, Michigan 48201

Received October 9, 1992; Revised Manuscript Received January 7, 1993

ABSTRACT: A galactoside-binding lectin (hL-31) containing a collagen-like sequence was identified in human tumor cells. It was found to be the homologue of the IgE-binding protein, the macrophage cell-surface Mac-2 antigen, and the murine CBP35, RL-29, and mL-34 lectins. Here we report on the expression in *Escherichia coli* and functional analysis of recombinant hL-31 (rhL-31). The rhL-31 was purified in one step through an asialofetuin affinity column. The rhL-31 was reactive to anti-lectin antibodies and retained its lactose-dependent hemagglutination of trypsin-treated glutaraldehyde-fixed rabbit erythrocytes. The rhL-31 elutes from an affinity column as a 31-kDa monomer and undergoes homodimerization at relatively high protein concentrations, comparable to those used to mediate hemagglutination. Electron microscopy showed that the rhL-31 appears as a Y-shaped structure. Lactoperoxidase-catalyzed iodination of murine tumor cell-surface proteins followed by collagenase treatment revealed that the lectin is probably a peripheral membrane protein whereby both the amino and the carboxy termini are exposed on the outer cell membrane. These results point to the membrane disposition and orientation of the lectin and suggest a mechanism for a structure–function relationship of lectin activity.

Coined the Name "Galectin" - 1992

1992, U.S. Department of Health and Human Services;
Journal of the National Cancer Institute

J Natl Cancer Inst 1992; 84: 438-442

March 18, 1992

SECTION: REPORTS

LENGTH: 2382 words

TITLE: Modulation of the Lung Colonization of B16-F1 Melanoma Cells by Citrus Pectin

AUTHOR: David Platt, Avraham Raz <1>

ABSTRACT: *Context:* Studies have shown that the galactoside-containing simple sugars and anti-galactoside-binding lectin antibodies may affect experimental tumor cell metastasis. However, the limited number of reagents used thus far necessitate further observations. *Purpose:* Natural citrus pectin (CP) and pH-modified CP (MCP), rich in galactose residues, were used to study the involvement of carbohydrates containing galactoside residues in cellular interaction in vitro and in lung colonization in vivo of B16-F1 melanoma cells. *Methods:* B16-F1 melanoma cells were incubated with various concentrations of CP and MCP. Their ability to form homotypic aggregation in vitro and tumor lung colonization in vivo in 8-week-old female C57BL/6 mice was then analyzed. *Results:* The CP binds to the surface of B16-F1 melanoma cells; this binding can be inhibited by lactose at a concentration of 0.15 *M*. Intravenous injection of the murine B16-F1 melanoma cells with the natural CP resulted in a significant increase (up to threefold) in the appearance of tumor colonies in the lung and in increased homotypic aggregation properties of the cells, while injection of MCP significantly decreased B16-F1 experimental metastasis (> 90%). *Conclusions:* Tumor galactoside-binding proteins mediate cellular recognition by linking oligosaccharides with terminal D-galactoside residues on adjacent cells. Successful interference with such a process with MCP may

Developing Broad-Spectrum Antiviral Galectin Antagonists for Humans & Animals

Complete Viral Clearance shown in 2 Randomized Controlled Clinical trials in a COVID19 Case Study

Expansion planned for follow on indications

COVID-19 * Influenza
RSV * HIV * Conjunctivitis * Shingles * Bird Flu

Bioxytran's ProLectin-M vs Pfizer's Paxlovid

- Day 3 – 14 out of 17 were PCR negative (**88%**)
- Day 7 – 17 out of 17 were PCR negative (**100%**) No toxicity signals
- Standard Risk Patients w/o limitations

- Day 20 PCR negative **(30%)**
- Toxicity (Drug to Drug Interactions)
- Limited to Underlying Medical Conditions.

Bioxytran's Phase 2 Data



Pfizer's Paxlovid Real World Data1



[1] https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00507-2/fulltext

ProLectin-M - Phase 2 Trial Results

Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print

Press Release
11/16/2022

PR Newswire

BOSTON, Nov. 16, 2022

- Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)
- Complete elimination of viral load in 88% of patients at day 3 vs 0% in placebo (p=.001)
- Treated population experienced no viral rebounds within the 14-day observation period

BOSTON, Nov. 16, 2022 /PRNewswire/ -- BIOXYTRAN, INC. (OTCQB: BIXT), (the "Company"), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced positive topline safety and efficacy results of its randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19. During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered 8 times per day on an hourly basis. The endpoint was a statistically significant reduction in viral load measured by the number of patients reaching a below threshold PCR value (Ct value ≥ 29) by day 7. The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value = .001). Our analysis also revealed an 88% response rate by day 3, which was statistically significant (p-value = .001). There were no drug-related serious adverse events (SAE's) in the patient population or viral rebounds by day 14 in the patient population. The positive data from this clinical trial provided the rationale of dosing and protocol design for study in an upcoming phase 2/3 registrational trial.

The full text of the preprint is located at the following link.
https://www.medrxiv.org/content/10.1101/2022.11.09.22282151v1

Possible COVID Resurgence is Brewing

More virulent COVID variant Spreading in Asia Europe & US

- Highly transmissible and showing immune evasion
- Cases of NB.1.8.1 and “Stratus” (XFG) Variants rising globally

Current Antivirals – First & Last Line of Defense

- Paxlovid
- Molnupiravir
- Remdesivir

($4.0 Bil Annually)

Existing Solutions are Inadequate

Resistance Emerging Rebounds No Prevention Side Effects



Bioxytran's ProLectin-M

First line of defense for all mutations of coronaviruses*

STATUS

Clinical Trial Stage. Phase II successfully completed– Phase III Ready under the Central Drugs Standard Control Organization (CDSCO) in India

Safety

- No Adverse Effects
- No Expected
- Limitations

Versatility

- Mutation Agnostic
- Therapeutic

Efficacy

Eliminate Contagion

Fast Patient Sterilization

PCR neg in 5 Days

https://www.longdom.org/abstract/galectin-antagonist-use-in-mild-cases-of-sarscov2-pilot-feasibility-randomised-open-label-controlled-trial-61087.html
Galectin approach to lower covid transmission - Drug Development for clinical use (medRxiv.org)

Neutralizing the Spike Protein on Viruses



Part of the Problem

Antibodies need a place to attach. The sugar shield is not static, but rather a dynamic shape shifting like coating with windshield wipers on the surface that limit areas of attachment.

How it Works

ANTIBODY



Galectin Fold

Conserved binding site
Common to all variants

Galectin Fold Ideal Binding Site

- ✓ Binding to the spike protein prevents viral entry
- ✓ Immensely tighter bond to galectin fold vs tip (ProLectin-RX 99% binding affinity)
- ✓ Antibodies take time to be produced – slower response to infection

Antibody Binding Site

Site prone to mutation Sugars can wipe off neutralizing antibodies

ProLectin Neutralizes the Virus by Binding to Galectin Receptors

Historic Discovery in Virology Similar to the discovery of Antibiotics

One Drug One Virus Concept Upheld Since the 1970's Debunked by ProLectin-M (50+ yrs)

ProLectin-M has Broad Spectrum Activity in COVID-19, RSV, Influenza (Patent for 60+ viruses)2

- Carbohydrate PL-M Binds Galectin-3 to inhibit SARS-CoV-2 Viral Entry Into Cells
- Evaluation of Complex Carbohydrates Showing Broad-Spectrum Antiviral Activity
- Research and Markets

DISCOVERY

Viral adhesion to the cellular membrane is the first step in the process of viral entry and galectins facilitate this process. Both viruses and cells are covered in slippery membranes. Galectins act as the viral glue that can tether the virus to the cell enabling the process of viral entry.1

Existing antivirals work on one virus or a couple mutations of a virus

They work by disrupting the life cycle of a virus once a cell is infected instead of neutralizing the virus outside the cell

No Broad-Spectrum Antivirals Currently Exist

Disrupting $55.36 billion Global Antiviral Mkt3

BioXyTran®

PROBLEM NUMBER #2

No Effective Treatment for Early-Stage Stroke

The Brain Stroke Epidemic

The Golden Hour Dilemma

Onset of symptoms

Ambulance arrives at home

Arrival and initial assessment and treatment in ER

Thombolysis or PTCA/CABG

Blockage Removed

Time to Needle

2.5 hours

Equivalent to 9 Years of Aging*

A Challenge to Worldwide Healthcare, a $500 Billion Medical Indication Costs

Region	Strokes/yr	Population	Survivors	Direct cost	Indirect cost
US	0.8 million	330 million	5.8 million	$44 billion	$22 billion
World (total)	12.2 million	7,700 million	33.0 million	estimated $500 billion	

BXT-25 Oxygen Bridge



- BXT-25 is a hemoglobin-based polymer; 5,000 times smaller than a red blood cell
- It can be used both in Ischemic and Hemorrhagic Stroke
- It can penetrate a blood-clot and reach the brain within 3 minutes
- Reduction of average Time-to-Needle by 90%

FDA Approved 510K To Detect Brain Oxygenation

MDX Viewer solely and exclusively licensed to Bioxytran by MDX Lifesciences Inc. – A clinical end-point for measuring oxygen delivery to the brain in real-time



Tissue/brain monitored parameters



- **Mitochondrial NADH (ATP)**
- **Hb Saturation (O_2)**
- **Cerebral Blood Flow**
- **Blood Volume**

Brain metabolic score

90

Tissue metabolic score

Measures real time tissue oxygenation levels

Assists in determining organ viability

BioXyTran®

Problem #3

No Effective Treatments for Cancer Metastasis

Clinical Evidence: Cancer Trial Results – Galectin-3



PET Scan Before and After of Melanoma patient is the Complete Response in Cohort 2
(All Tumors Resolved)

Galectin Antagonist therapy in Cohort 2 had a 100% Objective Response in advanced Melanoma for an 85-day trial using optimal dosage.

1 in 5 had a Complete Response

50% had Objective Response in Melanoma





Curti, B. D., et al. (2021). Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. Journal for ImmunoTherapy of Cancer, 9(4). https://doi.org/10.1136/jitc-2021-002371

Development Pipeline

BioXyTran®

Completed Planned

Product	Indication	Preclinical	IND Submission	Phase I	Phase II	Phase III	Phase IV
ProLectin-M **Oral**	**Virology – Mild to Moderate** • Covid-19 • Influenza • Other virologic diseases						
ProLectin-I/C **Intravenous**	**Virology – Severe cases** • [I] Covid-19, Long Covid • [I] Other virologic diseases • [C] Cancer Metastasis						
Blood Substitute UOC / BXT-25 **Intravenous**	**Stroke, Dementia, Sickle Cell Anemia** ARDS and other hypoxic conditions						
ProLectin-F **Intravenous**	**Oncology and Fibrosis:** • Pulmonary Fibrosis • NASH • Other Fibrotic conditions						

IP Strategy

Intellectual Property (IP)

- Three (3) issued worldwide patents
- One (1) licensed US patent
- Additional applications to strengthen our IP position are ongoing

Future patents to be filed at commercialization stage

International Patent Attorney

CLARK+ELBING

1. Pharmalectin has received an international trademark for ProLectin (WO0000001646681)
2. Patent issued in 2023 by the International Bureau of the Patent Cooperation Treaty (PCT) expiring in March 2042 (Lectin-binding carbohydrates for treating viral infections - WO2023178228A1)
3. Patent issued in 2022 by the International Bureau of the Patent Cooperation Treaty (PCT) expiring in February 2041 (Polysaccharides for iv administration that treat sars-cov-2 infections - WO2022099061A1)
4. MDX LifeSciences has licensed a patent (Tissue Metabolic Score for Patient Monitoring - US20210153816A1). Issued in 2021 by the U.S. Patent and Trademark Office (USPTO) expiring in February 2040
5. Patent issued in 2022 by the International Bureau of the Patent Cooperation Treaty (PCT) expiring in February 2041 (Polysaccharides for use in treating sars-cov-2 infections - WO2022099052A1)

Bioxytran's Exit Strategy

Licensing

Partnership

Divesting product line

COVID-19 Antiviral Comparables

Roche — $350 million

MERCK — $425 million

NOVARTIS — $850 million & 22% royalties

FIERCE Biotech

PharmaShots



The Team

MANAGEMENT

David Platt PhD

CEO, CSO, Chairman

Leader in Carbohydrate chemistry, founded five public companies, and led the development of numerous drugs and FDA regulatory clinical trials. Author of two Textbooks and publication of numerous Journal Articles and Patents. Found five public companies such as NASDAQ: GALT, NASDAQ: LJPC.

Ola Soderquist CPA, MSA, MBA,

CFO

>30 years of senior international entrepreneurial management experience within technology companies where he has served in CFO and other capacities.

Mike Sheikh,

CCO

>10 years of business development in life sciences. Broker and Research Analyst. US Air Force Academy graduate and pilot.

Dr. Leslie Ajayi MD

CMO, Board Member

>20 years of clinical development experience in academia and industry. A fully trained physician leader with international specialty training in internal medicine, cardiovascular medicine, and clinical pharmacology.

The Team

BOARD OF DIRECTORS

David Platt, PhD
Chairman Director

Chemical Engineer. Specialized in Complex Carbohydrate Chemistry. Created 5 public companies. Managed multiple clinical trials under FDA. Published two textbooks.

Radka Milanova, PhD
Director

Radka Milanova currently works at Allied Corp. (Canada), as Chief Scientific Director and BioXyTran, Inc., as Independent Director from 2024. Dr. Milanova received her doctorate degree from Simon Fraser University

Dale Conaway DVM
Director

Veterinary Medical Officer, Federal Research. Formerly Manager of the Equine Drug Testing and Animal Disease Surveillance Laboratories for the Michigan Department of Agriculture

Alan Hoberman PhD
Director

President and CEO of Argus International

Anders Utter MBA
Director Head of the Audit Committee

President and CEO Charles River Laboratories Preclinical Services (formerly Argus International, Inc. where he was the founder)

Advisory Board

Avraham Mayevsky PhD, Professor Emeritus

Worldwide authority in the field of minimal invasive monitoring of tissue and organ physiology; and professor at the Faculty of Life Sciences, Bar-Ilan University, Israel. published over 170 papers in scientific journals three textbooks and is the author of twelve patents

Kevin H Mayo, PhD

Professor of Biochemistry, Molecular Biology & Biophysics at the University of Minnesota (UMN). Known authority in the field of structural biology and structure-based drug design

Alben Sigamani, MD

Professor and Head of Clinical Research Narayan Health, Bangalore. >17 years of experience in clinical research

Symbol: BIXT (OTCQB)

SEC Fully Reporting Public Company (Audited)

- 2,100 Shareholders
- 89M Shares Outstanding
- 65%+ Insider Ownership
- 37M Shares in Float
- ~ $7M Market Cap

Location
Boston, MA

Formation
2017

Funding
Accredited Investors

Licensing Strategy – Multiple Big Pharma Partners

All IP Developed In-House
Focused on Carbohydrate Drug Design

OFFERING

Offering Amount

$2.4M

One Share @$0.06 Plus One Warrant @$0.12 Warrant Expires in 5 years

INSIDERS	68 %
OTHER RESTRICTED	100 %
FLOAT	41 %
TOTAL OUTSTANDING	89 million
TOTAL FULLY DILUTED	319 million

Use of Proceeds

Crossover Round – $2,400,000	ProLectin-M	
Estimated Project Cost in thousands USD	$	2,400
Development & GMP		1,040
Pre-Clinical		100
IND Submission		160
Clinical Trials		900
G&A		200
End Point		Phase III

BioXyTran®

Experienced Management Team

Demonstrated ability to navigate regulatory climate in record time & multiple jurisdictions

Cost Efficient Development

Funds spent on advancing clinical trial development not R&D

De Risked Science

Efficacy proven in peer-reviewed journals. For Viral Elimination. Regulatory approval to proceed in one indication

Value Inflection Point

Clinical Trial Milestone Successful. Phase II double blind placebo control is completed and ready to be announce!

Loyal Shareholder Base

Investors Interested in reaching regulatory milestones on budget

Licensing Platform

Once we reach regulatory approval the drug's Mechanism of action could lead to rapid label expansion w/ interested Big Pharma partners

BioXyTran®

David Platt

david.platt@bioxytraninc.com

BioXyTran®

BioXyTran®

75 2nd Ave., Suite 605 Needham MA, 02494

www.bioxytraninc.com

info@bioxytraninc.com